Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Endoxan often causes hair loss, which usually starts in the third week of treatment.

The committee unanimously voted against recommending approval of the injectable cisplatin/epinephrine gel IntraDose for certain head and neck cancer patients, citing insufficient clinical benefit and concerns about toxicity in this study.

In this case report, researchers detailed the clinical management and positive outcome of a 62-year-old woman with catastrophic antiphospholipid syndrome associated with systemic lupus erythematosus, highlighting the potential effectiveness of Eculizumab in achieving disease remission and maintaining stability over 18 months.

This article reviews the current status of oral retinoids in dermatology and reports no new clinical findings.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This case report described a patient with erosive pustular dermatosis of the scalp who was resistant to multiple treatments, suggesting that combination therapy may be more effective than monotherapy for managing refractory cases of this condition.

Fibroblasts from healthy donors can prevent changes seen in recessive epidermolysis bullosa simplex.

Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.

This study reported that while general patient characteristics and adverse event incidence for eribulin were comparable between a healthcare claims database and post-marketing surveillance, significant differences in some side effects such as neutropenia were observed.

This study found that mirex and TPA promote papilloma formation in CD-1 mouse skin through distinct populations of mutant Ha-ras cells, resulting in additive tumor yields.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This study concluded that while methotrexate-related adverse events were infrequent in early rheumatoid arthritis patients taking adalimumab, some increased with higher methotrexate doses, suggesting use of the lowest effective dose.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

This study found that high doses of ethyl acetate extract from Tridax procumbens can have specific toxic effects in rats, including organ damage and significant changes in some serum biochemical parameters.

In this study, a patient with Cronkhite-Canada syndrome complicated by severe sepsis and disseminated intravascular coagulation was successfully treated using combined therapies, including recombinant human soluble thrombomodulin, despite the absence of a standard treatment regimen for CCS.

The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.

This study found that the ethanol extract of Eclipta alba significantly reduced gastric lesions and enhanced gastroprotective activity in ulcer-induced rats, suggesting potent antisecretory effects potentially linked to antioxidant properties.

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

This document provides a legal disclaimer and offers no research findings.

This study found that the new cocrystal formulation KET-PABA improved the antimycotic efficiency of ketoconazole and induced an anti-inflammatory response without causing skin sensitization in mice.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

The UK High Court revoked Lundbeck's patent for Escitalopram, and second medical use claims based on dosage were not considered novel.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This review discusses the development and potential therapeutic effects of nitroxide small molecule agents for age-related macular degeneration and cardiovascular disease, but reports no new clinical results.

CRISPR/Cas9 and prime editing can potentially fix skin disorder genes safely and effectively.

This study developed HA-gel-dex hydrogels with enhanced ECM-like properties and functionality, showing promise for 3D bioprinting, tissue repair, and as wound dressings due to improved cell interaction, cytocompatibility, antimicrobial synergy, and wound healing in mice compared to traditional ECM bio-inks.

This review suggests that the compound DRDE-07, originally a sulphur-mustard countermeasure candidate, could potentially be repurposed for skin protection due to its compatibility with pathways involved in oxidative stress and inflammation, though further experimental study is needed to confirm its therapeutic applicability in dermatology.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.